Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide

NCT07713992 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)
Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus

Interventions

DRUG: Mazdutide(Dual GLP-1R/GCGR Agonist)
DRUG: Semaglutide (1 Mg Dose)

Sponsor

Tianjin Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]